Doxycycline Postexposure Prophylaxis for Sexually Transmitted Infection Prevention

References

1. 1.↵
   1. Luetkemeyer AF,
   2. Donnell D,
   3. Dombrowski JC

   , DoxyPEP Study Teamet al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 2023;388:1296–306.

   OpenUrlCrossRefPubMed
2. 2.↵
   Sexually transmitted disease surveillance 2021.Centers for Disease Control. Available at: https://www.cdc.gov/std/statistics/2021/default.htm. Accessed November 15, 2023.
3. 3.↵
   HIV Nexus clinician resources, guidelines and recommendations-Centers for Disease Control. Available at: https://www.cdc.gov/hiv/clinicians/guidelines/index.html#Prevention. Accessed November 15, 2023.
4. 4.↵
   1. Traeger MW,
   2. Cornelisse VJ,
   3. Asselin J

   , PrEPx Study Teamet al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 2019;321:1380–90.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Alaei K,
   2. Paynter CA,
   3. Juan S-C,
   4. Alaei A

   . Using preexposure prophylaxis, losing condoms? Preexposure prophylaxis promotion may undermine safe sex. AIDS 2016;30:2753–6.

   OpenUrlPubMed
6. 6.↵
   1. Molina JM,
   2. Charreau I,
   3. Chidiac C

   , ANRS IPERGAY Study Groupet al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018;18:308–17.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Oware K,
   2. et al

   . Characteristics of Kenyan women enrolled in a trial on doxycycine post-exposure prophylaxis for sexually transmitted infection prevention. doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial, 1 April 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/37270546/#:∼:text=Results%3A%20Between%20February%202020%20and,three%20months%20prior%20to%20enrolment.
8. 8.↵
   Guidelines for the use of doxycycline post-exposure prophylaxis for bacterial STI prevention-Centers for Disease Control. Available at: https://www.cdc.gov/std/treatment/guidelines-for-doxycycline.htm. Accessed November 15, 2023.
9. 9.↵
   1. Berçot B,
   2. Charreau I,
   3. Rousseau C

   , ANRS IPERGAY Study Groupet al. High prevalence and high rate of antibiotic resistance of Mycoplasma genitalium infections in men who have sex with men: a substudy of the ANRS IPERGAY Pre-exposure Prophylaxis Trial.
10. 10.↵
    1. Chan PA,
    2. Le Brazidec DL,
    3. Becasen JS,
    4. et al

    . Safety of longer-term doxycycline use: a systematic review and meta-analysis with implications for bacterial sexually transmitted infection chemoprophylaxis. Sex Transm Dis 2023;50:701–12.

    OpenUrlPubMed
11. 11.↵
    1. Whiley DM,
    2. Tickner JA,
    3. Kundu RL,
    4. Hogan TR,
    5. van Hal SJ,
    6. Lahra MM

    . Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis. Lancet Infect Dis 2023;23:e268–e269.

    OpenUrlCrossRefPubMed
12. 12.↵
    The Priority Updates from the Research Literature (PURLs) methodology. Available at: https://journals.lww.com/ebp/Documents/PURLs%20Methods%20AC.pdf.